Nebivolol Sandoz (Nebivolol Hydrochloride)

Nebivolol Hydrochloride, the active ingredient in Nebivolol Sandoz, is a beta‑adrenergic blocker presented as an oral tablet for oral use. It is prescribed to manage hypertension and to improve outcomes in patients with chronic heart failure by reducing heart rate and peripheral vascular resistance.

GNH USA supplies Nebivolol Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. Our distribution network ensures consistent quality and regulatory compliance across markets. We adhere to stringent quality standards to meet the needs of diverse healthcare systems.

Nebivolol is a selective β1‑adrenergic blocker used in cardiovascular disease management.

- Hypertension: lowers blood pressure by decreasing cardiac output and peripheral vascular resistance. - Heart failure: improves left ventricular systolic function and reduces the risk of hospitalization. - Isolated systolic hypertension in elderly patients: provides effective blood pressure control with a favorable heart‑rate profile.

Nebivolol is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Dizziness or light‑headedness, especially on standing. - Fatigue or general weakness. - Bradycardia: slower than normal heart rate. - Nasal congestion or mild upper‑respiratory irritation. - Nausea or mild gastrointestinal upset.

Serious or Rare Side Effects: - Severe bradycardia or symptomatic heart block. - Marked hypotension leading to syncope. - Acute bronchospasm in patients with reactive airway disease. - Allergic reactions such as rash, pruritus, or angioedema. - Worsening heart failure symptoms. - Hepatic enzyme elevations or liver injury.

Use of Nebivolol requires careful clinical assessment and monitoring.

- Blood pressure monitoring: ensure adequate control and avoid excessive hypotension. - Renal or hepatic impairment: dose adjustment may be necessary. - Asthma or chronic obstructive pulmonary disease: use with caution due to potential bronchospasm. - Abrupt discontinuation: taper gradually to prevent rebound hypertension. - Diabetes mellitus: monitor blood glucose as beta‑blockade may mask hypoglycaemia symptoms. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Nebivolol may interact with several drug classes; clinical judgment is essential.

Major Interactions (Avoid): - Combined use with other beta‑blockers: risk of excessive bradycardia and hypotension. - Calcium channel blockers verapamil or diltiazem: can potentiate negative cardiac effects. - Strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine): increase nebivolol plasma concentrations.

Moderate Interactions (Monitor Closely):\n- Non‑steroidal anti‑inflammatory drugs (NSAIDs): may reduce antihypertensive efficacy. - Diuretics: additive blood‑pressure lowering effect; monitor electrolytes. - Other antihypertensives (ACE inhibitors, ARBs): may require dose titration. - Insulin or oral hypoglycemics: beta‑blockade can mask hypoglycaemia signs. - Certain antidepressants (e.g., sertraline): monitor for bradycardia.